Stay updated on ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial
Sign up to get notified when there's something new on the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page.

Latest updates to the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedThe ClinicalTrials.gov record for the ACP-196 and pembrolizumab study is available, with details on its design, participants, treatment arms, results measures, and locations. It also includes the study protocol and statistical analysis plan.SummaryDifference42%

- Check16 days agoChange DetectedThe footer’s site revision identifier changes from v3.7.2 to v3.8.0; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check23 days agoChange DetectedA banner announces that NIH is transitioning its terminology from “Artificial Intelligence” to “Super Intelligence” and links to related updates and FAQs.SummaryDifference1%

- Check30 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check37 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1; the page continues to display a 403 error.SummaryDifference0.2%

- Check58 days agoChange DetectedThe page now displays a 403 Forbidden error, indicating the study record is not accessible. The usual study content and navigation are replaced by an error screen and site footer.SummaryDifference17%

Stay in the know with updates to ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACP-196/Pembrolizumab in Urothelial Bladder Cancer Clinical Trial page.